SAN FRANCISCO, June 21, 2017 /PRNewswire/ -- HelloMD, the nation's largest community of medical cannabis patients, experts, and trusted brands, announced today that they have partnered with PharmaCannis, a multi-region, vertically integrated medical cannabis provider. The two companies will work together to provide a complete end-to-end medical cannabis solution to existing and new patients. This collaboration will result in expanded access to cannabis expertise, physicians, education, and medical cannabis products. Effective immediately, HelloMD and PharmaCannis will focus on providing services in New York, with other states to follow.
In the past year, New York State has experienced significant and challenging growing pains since opening its program to patients. However, the recent addition of chronic pain to the list of qualifying conditions, coupled with a growing supply of certified healthcare practitioners who are qualified to make a medical cannabis recommendation, the program has seen a spike in demand.
"Given the tremendous differences in medical cannabis markets from state to state, partnering with best-in-class operators like PharmaCannis is absolutely critical for HelloMD as we work to expand patient access to medical cannabis. It is also an important step towards making our services available nationwide," said Larry Lisser, Senior Vice President of Business Development for HelloMD. "Aside from sharing a strong focus on the cannabis-related health and wellness market, the quality of the team at PharmaCannis makes them an ideal partner for our first launch outside California."
PharmaCannis will leverage a variety of HelloMD's partner solutions, including telemedicine service to develop new patient relationships; community solutions to engage further with prospective and existing patients; and HelloMD's product discovery platform to help patients learn more about the PharmaCannis lines of cannabinoid-based therapies. In addition to New York, PharmaCannis is currently serving patients in Illinois, will soon be operational in Massachusetts and Maryland, and has pending applications in both Pennsylvania and Ohio. The company expects to deploy HelloMD services in all of these states, where permissible.
"As PharmaCannis expands its product line and services in New York – and the state expands access to its program – we found a partner in HelloMD that could help us accelerate our reach and brand awareness across this growing market," said Jeremy Unruh, General Counsel of PharmaCannis. "HelloMD's stellar reputation in California along with their thoughtful approach to community-oriented services made working together a priority for us. We look forward to collaborating with HelloMD across all our markets."
